• 1
    Kusters MA, Verstegen RH, Gemen EF, de Vries E. Intrinsic defect of the immune system in children with Down syndrome: a review. Clin Exp Immunol 2009; 156:18993.
  • 2
    Nespoli L, Burgio GR, Ugazio AG, Maccario R. Immunological features of Down's syndrome: a review. J Intellect Disabil Res 1993; 37(Pt 6):54351.
  • 3
    Yang Q, Rasmussen SA, Friedman JM. Mortality associated with Down's syndrome in the USA from 1983 to 1997: a population-based study. Lancet 2002; 359:101925.
  • 4
    Spangrude GJ, Scollay R. Differentiation of hematopoietic stem cells in irradiated mouse thymic lobes. Kinetics and phenotype of progeny. J Immunol 1990; 145:36618.
  • 5
    Donskoy E, Foss D, Goldschneider I. Gated importation of prothymocytes by adult mouse thymus is coordinated with their periodic mobilization from bone marrow. J Immunol 2003; 171:356875.
  • 6
    Lorenzo LP, Chen H, Shatynski KE, Clark S, Yuan R, Harrison DE, Yarowsky PJ, Williams MS. Defective hematopoietic stem cell and lymphoid progenitor development in the Ts65Dn mouse model of Down syndrome: potential role of oxidative stress. Antioxid Redox Signal 2011; 15:208394.
  • 7
    Kirsammer G, Jilani S, Liu H, Davis E, Gurbuxani S, Le Beau MM, Crispino JD. Highly penetrant myeloproliferative disease in the Ts65Dn mouse model of Down syndrome. Blood 2008; 111:76775.
  • 8
    Serwold T, Ehrlich LI, Weissman IL. Reductive isolation from bone marrow and blood implicates common lymphoid progenitors as the major source of thymopoiesis. Blood 2009; 113:80715.
  • 9
    Sitnicka E, Buza-Vidas N, Ahlenius H et al. Critical role of FLT3 ligand in IL-7 receptor independent T lymphopoiesis and regulation of lymphoid-primed multipotent progenitors. Blood 2007; 110:295564.
  • 10
    Paz-Miguel JE, Flores R, Sanchez-Velasco P, Ocejo-Vinyals G, Escribano de Diego J, Lopez de Rego J, Leyva-Cobian F. Reactive oxygen intermediates during programmed cell death induced in the thymus of the Ts(1716)65Dn mouse, a murine model for human Down's syndrome. J Immunol 1999; 163:5399410.
  • 11
    Murphy M, Friend DS, Pike-Nobile L, Epstein LB. Tumor necrosis factor-α and IFN-γ expression in human thymus. Localization and overexpression in Down syndrome (trisomy 21). J Immunol 1992; 149:250612.
  • 12
    Larocca LM, Lauriola L, Ranelletti FO, Piantelli M, Maggiano N, Ricci R, Capelli A. Morphological and immunohistochemical study of Down syndrome thymus. Am J Med Genet Suppl 1990; 7:22530.
  • 13
    Roat E, Prada N, Lugli E et al. Homeostatic cytokines and expansion of regulatory T cells accompany thymic impairment in children with Down syndrome. Rejuvenation Res 2008; 11:57383.
  • 14
    Bloemers BL, Bont L, de Weger RA, Otto SA, Borghans JA, Tesselaar K. Decreased thymic output accounts for decreased naive T cell numbers in children with Down syndrome. J Immunol 2011; 186:45007.
  • 15
    Fry TJ, Mackall CL. The many faces of IL-7: from lymphopoiesis to peripheral T cell maintenance. J Immunol 2005; 174:65716.
  • 16
    Mazzucchelli R, Durum SK. Interleukin-7 receptor expression: intelligent design. Nat Rev Immunol 2007; 7:14454.
  • 17
    von Freeden-Jeffry U, Solvason N, Howard M, Murray R. The earliest T lineage-committed cells depend on IL-7 for Bcl-2 expression and normal cell cycle progression. Immunity 1997; 7:14754.
  • 18
    Peschon JJ, Morrissey PJ, Grabstein KH et al. Early lymphocyte expansion is severely impaired in interleukin 7 receptor-deficient mice. J Exp Med 1994; 180:195560.
  • 19
    Takada K, Jameson SC. Naive T cell homeostasis: from awareness of space to a sense of place. Nat Rev Immunol 2009; 9:82332.
  • 20
    Gonzalez-Garcia S, Garcia-Peydro M, Martin-Gayo E et al. CSL-MAML-dependent Notch1 signaling controls T lineage-specific IL-7Rα gene expression in early human thymopoiesis and leukemia. J Exp Med 2009; 206:77991.
  • 21
    Allman D, Sambandam A, Kim S, Miller JP, Pagan A, Well D, Meraz A, Bhandoola A. Thymopoiesis independent of common lymphoid progenitors. Nat Immunol 2003; 4:16874.
  • 22
    Godfrey DI, Kennedy J, Suda T, Zlotnik A. A developmental pathway involving four phenotypically and functionally distinct subsets of CD3 CD4 CD8 triple-negative adult mouse thymocytes defined by CD44 and CD25 expression. J Immunol 1993; 150:424452.
  • 23
    Sallusto F, Geginat J, Lanzavecchia A. Central memory and effector memory T cell subsets: function, generation, and maintenance. Annu Rev Immunol 2004; 22:74563.
  • 24
    Matthias P, Rolink AG. Transcriptional networks in developing and mature B cells. Nat Rev Immunol 2005; 5:497508.
  • 25
    Nagasawa T. Microenvironmental niches in the bone marrow required for B-cell development. Nat Rev Immunol 2006; 6:10716.
  • 26
    Allman D, Pillai S. Peripheral B cell subsets. Curr Opin Immunol 2008; 20:14957.
  • 27
    Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(–ΔΔ C(T)) method. Methods 2001; 25:4028.
  • 28
    Barrena MJ, Echaniz P, Garcia-Serrano C, Cuadrado E. Imbalance of the CD4+ subpopulations expressing CD45RA and CD29 antigens in the peripheral blood of adults and children with Down syndrome. Scand J Immunol 1993; 38:3236.
  • 29
    Anderson SM, Tomayko MM, Ahuja A, Haberman AM, Shlomchik MJ. New markers for murine memory B cells that define mutated and unmutated subsets. J Exp Med 2007; 204:210314.
  • 30
    Namen AE, Lupton S, Hjerrild K et al. Stimulation of B-cell progenitors by cloned murine interleukin-7. Nature 1988; 333:5713.
  • 31
    Munitic I, Williams JA, Yang Y, Dong B, Lucas PJ, El Kassar N, Gress RE, Ashwell JD. Dynamic regulation of IL-7 receptor expression is required for normal thymopoiesis. Blood 2004; 104:416572.
  • 32
    Ferrando-Miguel R, Cheon MS, Yang JW, Lubec G. Overexpression of transcription factor BACH1 in fetal Down syndrome brain. J Neural Transm Suppl 2003; 67:193205.
  • 33
    Sun J, Hoshino H, Takaku K et al. Hemoprotein Bach1 regulates enhancer availability of heme oxygenase-1 gene. EMBO J 2002; 21:521624.
  • 34
    Venugopal R, Jaiswal AK. Nrf1 and Nrf2 positively and c-Fos and Fra1 negatively regulate the human antioxidant response element-mediated expression of NAD(P)H:quinone oxidoreductase1 gene. Proc Natl Acad Sci USA 1996; 93:149605.
  • 35
    Wakabayashi N, Shin S, Slocum SL et al. Regulation of notch1 signaling by nrf2: implications for tissue regeneration. Sci Signal 2010; 3:ra52.
  • 36
    Kuhn DE, Nuovo GJ, Terry AV Jr et al. Chromosome 21-derived microRNAs provide an etiological basis for aberrant protein expression in human Down syndrome brains. J Biol Chem 2010; 285:152943.
  • 37
    Baltimore D, Boldin MP, O'Connell RM, Rao DS, Taganov KD. MicroRNAs: new regulators of immune cell development and function. Nat Immunol 2008; 9:83945.
  • 38
    Lewis BP, Burge CB, Bartel DP. Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell 2005; 120:1520.
  • 39
    Costinean S, Zanesi N, Pekarsky Y, Tili E, Volinia S, Heerema N, Croce CM. Pre-B cell proliferation and lymphoblastic leukemia/high-grade lymphoma in Eµ-miR155 transgenic mice. Proc Natl Acad Sci USA 2006; 103:70249.
  • 40
    Murphy M, Epstein LB. Down syndrome (DS) peripheral blood contains phenotypically mature CD3+ TCRαβ+ cells but abnormal proportions of TCR αβ+, TCR γδ+, and CD4+ CD45RA+ cells: evidence for an inefficient release of mature T cells by the DS thymus. Clin Immunol Immunopathol 1992; 62:24551.
  • 41
    Lima FA, Moreira-Filho CA, Ramos PL et al. Decreased AIRE expression and global thymic hypofunction in Down syndrome. J Immunol 2011; 187:342230.
  • 42
    Grabstein KH, Waldschmidt TJ, Finkelman FD, Hess BW, Alpert AR, Boiani NE, Namen AE, Morrissey PJ. Inhibition of murine B and T lymphopoiesis in vivo by an anti-interleukin 7 monoclonal antibody. J Exp Med 1993; 178:25764.
  • 43
    Vella A, Teague TK, Ihle J, Kappler J, Marrack P. Interleukin 4 (IL-4) or IL-7 prevents the death of resting T cells: stat6 is probably not required for the effect of IL-4. J Exp Med 1997; 186:32530.
  • 44
    Rathmell JC, Farkash EA, Gao W, Thompson CB. IL-7 enhances the survival and maintains the size of naive T cells. J Immunol 2001; 167:686976.
  • 45
    Kaech SM, Tan JT, Wherry EJ, Konieczny BT, Surh CD, Ahmed R. Selective expression of the interleukin 7 receptor identifies effector CD8 T cells that give rise to long-lived memory cells. Nat Immunol 2003; 4:11918.
  • 46
    Dhakshinamoorthy S, Jain AK, Bloom DA, Jaiswal AK. Bach1 competes with Nrf2 leading to negative regulation of the antioxidant response element (ARE)-mediated NAD(P)H:quinone oxidoreductase 1 gene expression and induction in response to antioxidants. J Biol Chem 2005; 280:16891900.
  • 47
    Burgio GR, Ugazio AG, Nespoli L, Marcioni AF, Bottelli AM, Pasquali F. Derangements of immunoglobulin levels, phytohemagglutinin responsiveness and T and B cell markers in Down's syndrome at different ages. Eur J Immunol 1975; 5:6003.
  • 48
    Rigas DA, Elsasser P, Hecht F. Impaired in vitro response of circulating lymphocytes to phytohemagglutinin in Down's syndrome: dose– and time–response curves and relation to cellular immunity. Int Arch Allergy Appl Immunol 1970; 39:587608.
  • 49
    Costa-Carvalho BT, Martinez RM, Dias AT et al. Antibody response to pneumococcal capsular polysaccharide vaccine in Down syndrome patients. Braz J Med Biol Res 2006; 39:158792.
  • 50
    Epstein LB, Philip R. Abnormalities of the immune response to influenza antigen in Down syndrome (trisomy 21). Prog Clin Biol Res 1987; 246:16382.
  • 51
    Melchionda F, Fry TJ, Milliron MJ, McKirdy MA, Tagaya Y, Mackall CL. Adjuvant IL-7 or IL-15 overcomes immunodominance and improves survival of the CD8+ memory cell pool. J Clin Invest 2005; 115:117787.
  • 52
    Fernandez-Martinez J, Vela EM, Tora-Ponsioen M, Ocana OH, Nieto MA, Galceran J. Attenuation of Notch signalling by the Down-syndrome-associated kinase DYRK1A. J Cell Sci 2009; 122:157483.
  • 53
    Verstegen RH, Kusters MA, Gemen EF, de Vries E. Down syndrome B-lymphocyte subpopulations, intrinsic defect or decreased T-lymphocyte help. Pediatr Res 2010; 67:5639.